Oct 15 (Reuters) - Novartis AG NOVN.S :
* NOVARTIS PHARMACEUTICALS CANADA - HEALTH CANADA HAS APPROVED LUXTURNA, A ONE-TIME GENE THERAPY
* NOVARTIS PHARMACEUTICALS CANADA - LUXTURNA APPROVED FOR TREATMENT OF ADULT & PEDIATRIC PATIENTS WITH VISION LOSS DUE TO INHERITED RETINAL DYSTROPHY